The Promise of Famotidine as a Possible Low-Cost COVID-19 Treatment

The Promise of Famotidine as Possible Low Cost COVID-19 Treatment

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

Since the beginning of the pandemic, scientists have been wondering why some people get very sick while others don’t. The answer could relate to the responses of individuals’ mast cells to infection. Therapies to blunt their response appear to be effective, most commonly over- the- counter H2 blocker famotidine (Pepcid). Numerous observational studies suggested its effectiveness, but they garnered little attention from the medical-research establishment pecking order. Several experts started writing that mast cells may be the key, yet the National Institutes of Health (NIH) exhibited little interest. The American Association of Asthma Allergy and Immunology initially expressed interest but abruptly became disinterested. During the pandemic, the emphasis of the NIH hasn’t been on cost-effective early care to save lives but rather the allocation of what will amount to hundreds of billions to develop and distribute vaccines and exotic treatments that very well could have been complemented with low-cost pragmatic, economic medicine. Given over 700,000 deaths in ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee